The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
N-SAS BC06: A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole (LET): The New Primary Endocrine-Therapy Origination Study (NEOS).
Hiroji Iwata
No relevant relationships to disclose
Shoichiro Ohtani
No relevant relationships to disclose
Tomomi Fujisawa
No relevant relationships to disclose
Naruto Taira
No relevant relationships to disclose
Norikazu Masuda
Honoraria - Chugai Pharma
Masahiro Kashiwaba
Research Funding - Chugai Pharma
Yutaka Yamamoto
No relevant relationships to disclose
Tatsuya Toyama
No relevant relationships to disclose
Takuhiro Yamaguchi
Consultant or Advisory Role - Novartis